Brokerages Set Regulus Therapeutics Inc. (NASDAQ:RGLS) Target Price at $7.25

Shares of Regulus Therapeutics Inc. (NASDAQ:RGLS - Get Free Report) have been given a consensus recommendation of "Moderate Buy" by the five research firms that are currently covering the firm, Marketbeat reports. One analyst has rated the stock with a hold recommendation and four have issued a buy recommendation on the company. The average 12 month target price among brokerages that have updated their coverage on the stock in the last year is $7.25.

A number of research firms have weighed in on RGLS. SVB Leerink started coverage on shares of Regulus Therapeutics in a research note on Monday, March 18th. They set an "outperform" rating and a $6.00 price target on the stock. Leerink Partnrs reiterated an "outperform" rating on shares of Regulus Therapeutics in a report on Monday, March 18th. Wells Fargo & Company upped their price target on Regulus Therapeutics from $2.00 to $3.00 and gave the stock an "equal weight" rating in a research note on Wednesday, March 13th. Canaccord Genuity Group reduced their price objective on Regulus Therapeutics from $12.00 to $11.00 and set a "buy" rating on the stock in a research note on Tuesday, March 19th. Finally, StockNews.com started coverage on Regulus Therapeutics in a report on Tuesday, April 16th. They set a "sell" rating for the company.

Regulus Therapeutics Price Performance

NASDAQ:RGLS traded down $0.20 during mid-day trading on Tuesday, reaching $2.23. The company's stock had a trading volume of 704,742 shares, compared to its average volume of 2,247,455. The stock has a market cap of $145.98 million, a P/E ratio of -1.40 and a beta of 1.59. The company's fifty day simple moving average is $2.34 and its two-hundred day simple moving average is $1.69. Regulus Therapeutics has a twelve month low of $1.08 and a twelve month high of $3.79.

Regulus Therapeutics (NASDAQ:RGLS - Get Free Report) last announced its quarterly earnings data on Thursday, March 21st. The biopharmaceutical company reported ($0.40) earnings per share for the quarter, hitting the consensus estimate of ($0.40). Sell-side analysts expect that Regulus Therapeutics will post -0.52 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Victory Capital Management Inc. raised its holdings in shares of Regulus Therapeutics by 5.3% during the 3rd quarter. Victory Capital Management Inc. now owns 233,207 shares of the biopharmaceutical company's stock valued at $322,000 after buying an additional 11,701 shares during the period. CVI Holdings LLC acquired a new stake in Regulus Therapeutics in the first quarter valued at approximately $4,050,000. FMR LLC raised its stake in shares of Regulus Therapeutics by 32.4% during the third quarter. FMR LLC now owns 2,922,600 shares of the biopharmaceutical company's stock valued at $4,033,000 after purchasing an additional 716,000 shares during the period. Finally, Vivo Capital LLC acquired a new position in shares of Regulus Therapeutics during the first quarter worth $14,400,000. Institutional investors and hedge funds own 92.38% of the company's stock.

Regulus Therapeutics Company Profile

Regulus Therapeutics Inc, a clinical stage biopharmaceutical company, focuses on discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RG-012, an anti-miR targeting miR-21 that is in Phase II clinical trial for the treatment of Alport syndrome, a life-threatening kidney disease; and RGLS8429, an anti-miR targeting miR-17, which is in Phase 1b clinical study for the treatment of autosomal dominant polycystic kidney disease.